CD244 Monoclonal Antibody (eBioPP35 (PP35)), Functional Grade, eBioscience™, Invitrogen™

Description

• Description: The eBioPP35 monoclonal antibody reacts with human CD244, also known as 2B4, p38, NK-cell activation-inducing ligand, signaling lymphocyte activation molecule family member 4, and natural killer cell receptor 2B4
• Human CD244 is a 38 kD protein expressed on NK cells, a subset of CD8+ T cells, gammadelta T cells, monocytes, basophils, mast cells, and eosinophils
• Binding of CD244 to its ligand, CD48, results in NK cell activation
• Costaining experiments with eBioC1.7 suggest that both antibodies recognize different epitopes
• Applications Tested: This eBioPP35 (PP35) antibody has been tested by flow cytometric analysis of human peripheral blood cells
• Storage and handling: Use in a sterile environment
• Filtration: 0.2 μm post-manufacturing filtered
• Purity: Greater than 90%, as determined by SDS-PAGE
• Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay
• Aggregation: Less than 10%, as determined by HPLC
• CD244 (2B4, SLAMF4) is a cell surface receptor expressed on natural killer (NK) cells (and some T cells) that mediate non-major histocompatibility complex (MHC) restricted killing
• The interaction between NK-cell and target cells via CD244 is thought to modulate NK-cell cytolytic activity
• CD244 interacts with SLAMF2, causing the activation of both SLAMF4- and SLAMF2-expressing cells
• Patients with systemic lupus erythmatosus have lower than normal levels of SLAMF4 expressed on their NK cells and monocytes, suggesting that SLAMF4 may play a role in the pathology of this autoimmune disease
• Diseases associated with CD244 dysfunction include rheumatoid arthritis and lymphoproliferative syndrome
• Alternatively spliced transcript variants encoding different isoforms of CD244 have been found for this gene.